Chemical Pathology of Acute Renal Failure (ARF/AKI)

• Brenner and Rector's The Kidney, p. 1243
• Goldman-Cecil Medicine, p. 1169

1. Nitrogenous Waste Retention (Azotemia/Uraemia)

• Blood Urea Nitrogen (BUN): Rises sharply as GFR falls. Since urea is filtered at the glomerulus and not adequately cleared, serum BUN rises - typically >20 mg/dL, and in oliguric ARF may exceed 100 mg/dL. The BUN:creatinine ratio (normally 10:1-20:1) is clinically useful: >20:1 suggests prerenal azotemia (increased tubular urea reabsorption with preserved creatinine clearance); <10:1 suggests intrinsic renal disease or rhabdomyolysis.
• Serum Creatinine: Rises with a fall in GFR (inverse relationship). In ARF, serum creatinine typically rises by 0.5-1.0 mg/dL/day in oliguric patients and 0.2-0.5 mg/dL/day in non-oliguric patients. KDIGO staging requires a rise of ≥0.3 mg/dL over 48 hours or ≥50% over 7 days.
• Uremia: At very high urea and creatinine levels, retention of multiple uremic toxins (phenols, guanidines, indoles, middle molecules) causes the clinical syndrome of uremia - nausea, vomiting, asterixis, pericarditis, encephalopathy.
• Goldman-Cecil Medicine, p. 1169; Brenner and Rector's The Kidney

2. Electrolyte Disturbances

Hyperkalemia

• The most immediately life-threatening chemical abnormality in ARF.
• As GFR falls, potassium excretion is severely impaired. In oliguric ARF, serum K⁺ may rise by 0.5 mEq/L/day or faster. Catabolic states, tissue necrosis (e.g. rhabdomyolysis), and metabolic acidosis all accelerate the rise (acidosis drives K⁺ out of cells in exchange for H⁺, raising serum K⁺ by ~0.5 mEq/L for every 0.1-unit fall in pH).
• Levels >6.5 mEq/L cause ECG changes (peaked T waves, widened QRS, sine wave pattern) and cardiac arrest.
• Henry's Clinical Diagnosis and Management by Laboratory Methods

Hyponatremia

• Despite total body sodium excess (due to impaired excretion), dilutional hyponatremia occurs when free water intake exceeds the capacity for water excretion. Serum sodium is often low-normal or mildly reduced.

Hypocalcemia

• Occurs particularly in rhabdomyolysis-associated ARF: calcium chelates with the released phosphate from necrotic muscle, depositing as calcium phosphate in soft tissues.
• Hyperphosphatemia (see below) further drives calcium down.
• Impaired renal 1-hydroxylation of vitamin D reduces 1,25-dihydroxycholecalciferol (calcitriol) production, contributing to hypocalcemia in prolonged ARF.

Hyperphosphatemia

• Phosphate, normally filtered and excreted by the kidney, accumulates in ARF. This is especially pronounced in rhabdomyolysis and tumor lysis syndrome, where massive cellular breakdown releases intracellular phosphate.
• Elevated phosphate chelates calcium, worsening hypocalcemia.

Hyperuricemia

• Uric acid, a breakdown product of purines, rises in ARF - particularly in tumor lysis syndrome and rhabdomyolysis. Urate crystal deposition in tubules can itself perpetuate the renal injury.
• Rosen's Emergency Medicine; Goldman-Cecil Medicine; Brenner and Rector's The Kidney

3. Metabolic Acidosis (High Anion Gap)

• The kidney normally excretes ~50-100 mEq of acid per day and regenerates bicarbonate. In ARF, this is severely impaired.
• Accumulation of:
  • Sulfuric acid (from sulfur-containing amino acid catabolism)
  • Phosphoric acid (from phosphate-rich organic compound catabolism)
  • Organic acids (lactic acid, keto acids if concurrent hepatic dysfunction or starvation)
• Bicarbonate (HCO₃⁻) is consumed buffering these acids, typically falling by 1-2 mEq/L/day. A high anion gap metabolic acidosis results (anion gap = Na⁻ - [Cl⁻ + HCO₃⁻]; normal 8-12 mEq/L; in ARF may exceed 20-24 mEq/L).
• Acidosis is both a direct chemical result and an aggravating factor for hyperkalemia and cardiac dysrhythmias.

4. Fluid and Volume Disturbances

• Oliguria/Anuria: In oliguric ARF, urine output falls to <400 mL/day (<100 mL/day in anuria). This impairs excretion of all solutes and free water, leading to volume overload.
• Volume overload: Manifests as pulmonary edema, hypertension, peripheral edema.
• Fractional excretion of sodium (FENa): Key to distinguish prerenal from intrinsic ARF.
  • Prerenal: FENa <1% (avid tubular sodium reabsorption intact)
  • Intrinsic ARF (e.g., ATN): FENa >2-3% (tubular damage impairs sodium reabsorption)
  • Fractional excretion of urea (FEUrea) is useful when diuretics have been administered.

5. Urinary Biochemistry

• Brenner and Rector's The Kidney; DiMaio's Forensic Pathology

6. Other Chemical Changes

• Anemia: Dilutional (volume overload), hemolysis (in certain forms), or early suppression of erythropoietin production in prolonged ARF.
• Hypermagnesemia: Can develop in ARF, especially with magnesium-containing antacid use.
• Elevated LDH, CK: Especially in rhabdomyolysis-associated ARF.
• Uric acid: Elevated in catabolic states and tumor lysis.

Pathophysiology of Chronic Renal Failure (CRF/CKD)

• Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 872; Goldman-Cecil Medicine, p. 1341

I. The Intact Nephron Hypothesis and Remnant Nephron Adaptations

Hyperfiltration-Hyperperfusion

1. Compensatory glomerular hypertrophy occurs in surviving nephrons.
2. Afferent arteriolar vasodilation (greater than efferent) increases blood flow to individual glomeruli.
3. Glomerular capillary hydrostatic pressure rises (glomerular hypertension).
4. Single-nephron GFR (SNGFR) rises - adaptive hyperfiltration - to maintain overall GFR.

• Elevated intraglomerular pressure mechanically stresses mesangial cells and podocytes.
• Increased filtration drives more protein (albumin) across the capillary wall - proteinuria.
• Proteinuria and protein reabsorption by tubular cells are directly tubulotoxic (activate inflammation, NF-kB, cytokines, fibrosis pathways).
• Glomerular hypertension leads to focal segmental glomerulosclerosis (FSGS) in surviving nephrons.
• This creates a vicious cycle: loss of more nephrons → further hyperfiltration in remaining nephrons → more glomerular injury → progressive nephron loss.

• Goldman-Cecil Medicine, p. 1341-1342; Comprehensive Clinical Nephrology, 7th Edition; Robbins Pathologic Basis of Disease

II. Role of the Renin-Angiotensin-Aldosterone System (RAAS)

• Reduced renal perfusion (from nephron loss, hypertension, scarring) activates the RAAS.
• Angiotensin II preferentially constricts the efferent arteriole, initially maintaining GFR but elevating intraglomerular pressure.
• Angiotensin II also directly promotes mesangial cell proliferation, extracellular matrix deposition, TGF-β release, and tubular apoptosis - independent of hemodynamic effects.
• Aldosterone causes sodium and water retention, worsening hypertension and volume overload.

III. Systemic Hypertension and the Kidney

• Most CKD patients develop hypertension (starts at GFR stages G1-G3), driven by:
  • Sodium and water retention (impaired excretion)
  • RAAS activation
  • Reduced vasodilatory prostaglandins and nitric oxide
• Hypertension further damages glomeruli through increased filtration pressure (nephrosclerosis) and accelerates CKD progression - a second vicious cycle.

IV. Proteinuria and Tubulointerstitial Injury

• Proteinuria is not just a marker - it is a direct mediator of progressive CKD.
• Filtered proteins (albumin, transferrin, complement factors) are taken up by proximal tubular cells, triggering inflammatory signaling.
• This causes tubular cell apoptosis, interstitial infiltration by macrophages/T-cells, fibroblast activation, and eventually interstitial fibrosis and tubular atrophy (IFTA) - the hallmark of CKD progression on biopsy.

V. Metabolic Consequences (Uremic Syndrome)

Key Endocrine Failures in CKD

1. Erythropoietin deficiency → normochromic, normocytic anaemia of CKD (starts at GFR ~30-40 mL/min). Peritubular fibroblasts in the cortex are the main EPO-producing cells; fibrosis destroys them.
2. 1,25-dihydroxyvitamin D₃ (calcitriol) deficiency → impaired 1α-hydroxylase activity in damaged tubules → reduced intestinal calcium absorption → hypocalcaemia → secondary hyperparathyroidism → renal osteodystrophy (osteomalacia, osteitis fibrosa cystica, osteopenia, growth retardation in children).
3. Secondary hyperparathyroidism: Phosphate retention suppresses calcitriol, and hypocalcaemia directly stimulates PTH secretion. Elevated PTH mobilises calcium and phosphate from bone. Prolonged stimulation can cause autonomous (tertiary) hyperparathyroidism.

• Robbins Pathologic Basis of Disease, p. 882; Goldman-Cecil Medicine

VI. Cardiovascular Pathophysiology

• CKD is an independent, major risk factor for cardiovascular disease (CVD). CVD is the leading cause of death in CKD patients, even before ESKD is reached.
• Mechanisms include:
  • Uremic toxin-mediated endothelial dysfunction
  • Hypertension and volume overload causing left ventricular hypertrophy
  • Anaemia (increases cardiac output demand)
  • Hyperphosphatemia and elevated FGF-23 causing vascular calcification
  • Dyslipidaemia (low HDL, high triglycerides from altered lipoprotein lipase activity)
  • Chronic inflammation (elevated CRP, IL-6)

VII. Mechanisms of CKD Progression - Summary

Initial Nephron Injury (DM, HTN, GN, etc.)
        ↓
Nephron Loss → Reduced GFR
        ↓
Compensatory Hyperfiltration in Remnant Nephrons
        ↓
Intraglomerular Hypertension + Hypertrophy
        ↓
Proteinuria → Tubulotoxicity → Interstitial Inflammation
        ↓
TGF-β, Angiotensin II, Aldosterone → Fibrosis
        ↓
Progressive IFTA (Interstitial Fibrosis + Tubular Atrophy)
        ↓
Further Nephron Loss → Vicious Cycle → ESKD

Key Sources

• Brenner and Rector's The Kidney, 2-Volume Set - AKI definition, staging, pathophysiology (pp. 1243-1250)
• Goldman-Cecil Medicine - Chemical approach to renal failure, CKD mechanisms and uremic syndrome (pp. 1169, 1341-1342)
• Robbins, Cotran & Kumar Pathologic Basis of Disease - CKD morphology, renal osteodystrophy, hyperfiltration (p. 872, 882)
• Comprehensive Clinical Nephrology, 7th Edition - Hyperfiltration hypothesis, RAAS, CKD progression (p. 1115)
• Henry's Clinical Diagnosis and Management by Laboratory Methods - Hyperkalemia and ARF
• Rosen's Emergency Medicine - Indications for dialysis in ARF (metabolic acidosis, hyperkalemia, uremia, oliguria)